UK-based Trimtech Therapeutics, a biotech harnessing targeted protein degradation (TPD) for neurodegenerative diseases, has ...

Israel-based Pluri, a biotech using its platform for cell-based solutions to create a collaborative network of ventures, was ...

Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire US biopharma company Chimerix ...

The Department of Government Efficiency (DOGE), led by Tesla chief executive Elon Musk, has terminated leases for 30 US Food ...

The US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for ...

Pliant Therapeutics has scrapped its Phase IIb Beacon-IPF trial for bexotegrast in idiopathic pulmonary fibrosis (IPF), after ...

German life science giant Bayer has reported 2024 group revenue of 47.6 billion euros ($51.5 billion), down 2.2% from the ...

The board of directors at immunology-focused biopharma Acelyrin (Nasdaq: SLRN) has found that an unsolicited takeover bid ...

Leading pharmaceutical associations in Russia have called on the government to postpone the introduction of new procurement ...

Swiss generics and biosimilars giant Sandoz today announced financial results for the full year 2024, showing that sales were ...

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing ...

IN8bio has unveiled a new T cell engager (TCE) platform, marking its first major push into autoimmune disease. The biotech, which previously focused on oncology, introduced INB-619, a CD19-targeted ...